Drugs /

hpv e6/e7 dna vaccine gx-188e

Back to Drugs List

Overview

NCI Definition [1]:
A therapeutic DNA vaccine encoding the E6/E7 fusion protein of human papillomavirus (HPV) subtypes 16 and 18, plus the immune-enhancer, Fms-like tyrosine kinase-3 ligand (FLT3L), with potential immunostimulating and antineoplastic activities. DNA vaccine GX-188E is administered using a proprietary delivery system that electroporates the vaccine into cervical cells. Expression of the E6/E7 fusion product may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 oncoproteins, resulting in tumor cell lysis. FLT3L is a ligand for the FLT3 tyrosine kinase receptor, which upon activation stimulates the proliferation of hematopoietic progenitor cells. HPV type 16 and 18 are the most common HPV types involved in cervical carcinogenesis.

Clinical Trials

View Clinical Trials for hpv e6/e7 dna vaccine gx-188e

Hpv e6/e7 dna vaccine gx-188e has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating hpv e6/e7 dna vaccine gx-188e, 1 is phase 1/phase 2 (1 open).

CDKN2A Overexpression and HPV Positive are the most frequent biomarker inclusion criteria for hpv e6/e7 dna vaccine gx-188e clinical trials.

Cervical carcinoma is the most common disease being investigated in hpv e6/e7 dna vaccine gx-188e clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Hpv E6/e7 Dna Vaccine Gx-188e
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating hpv e6/e7 dna vaccine gx-188e and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hpv e6/e7 dna vaccine gx-188e, gx-188e
NCIT ID [1]:
C102787

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.